Neuphoria Therapeutics Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Neuphoria Therapeutics Inc 's ROA in the fourth quarter of 2026?
Neuphoria Therapeutics Inc recorded a cumulative net loss of $-13 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -34.87%.

However, within the Healthcare sector 503 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3979, from total ROA ranking in the third quarter of 2026 at 4016.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	-1.36 %	13.33 %	100.89 %	19.32 %	-0.32 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-13	-17	-6	-9	0
Return On Assets (TTM)	-34.87 %	-44.96 %	-15.01 %	-28.64 %	-1.16 %
NEUP's Total Ranking	# 3979	# 4016	# 3860	# 2769	# 2920
Total Assets (TTM) in million	55	35	37	27	56
Seq. Total Assets Change	57.68 %	-6.61 %	36.31 %	-50.86 %	81.16 %
Seq. Net Income Change	-	-	-	-	-

NEUP's 5 Years Annual ROA >> Back to NEUP Management Effectiveness >> Compare NEUP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 201
Sector	# 504
Overall	# 3783

Return On Assets Statistics
High	Average	Low
-1.47 %	-35.71 %	-61.95 %
(Jun 30 2025)		(Jun 30 2024)

Financial Statements
Neuphoria Therapeutics Inc 's Assets	$ 55 million	NEUP's Balance sheet
Neuphoria Therapeutics Inc 's Income	$ -5 million	Quarterly NEUP's Income Statement
NEUP's Income by Division		See NEUP's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	-1.36 %	-0.32 %	-20.3 %	37.54 %	-
Total Assets in million	55	56	56	70	51
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	0	-15	-21	-16
Annual Return On Assets	-24.51 %	-0.66 %	-27.75 %	-30.53 %	-31 %

NEUP's 5 Years Annual ROA >> Back to NEUP Management Effectiveness >> Compare NEUP ROA to its Competitors

More Return On Assets Ratios
NEUP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NEUP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NEUP's Competitors
Subscribers only: Roa for Neuphoria Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for NEUP's Customers

You may also want to know
NEUP's Roi	NEUP's Inventory Turnover Ratio	NEUP's Growth Rates	NEUP's Dividend Comparisons
	NEUP's Profitability Ratios	NEUP's Asset Turnover Ratio	NEUP's Dividend Growth
NEUP's Roe	NEUP's Valuation Ratios	NEUP's Financial Strength Ratios	NEUP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-19T15:06:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.